Compare Enveric Biosciences Inc (ENVB) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Hilton Hotels Corporation Common Stock trades at $316 (market cap $70.00B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 11290.3× Enveric Biosciences Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HLT | |
|---|---|---|
Market Cap | $6.20M | $70.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $350.22 |
52-Week Low | $1.27 | $256.75 |
Enterprise Value | $1.30M | $83.01B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
Hilton Worldwide (HLT) trades at $317.60, down 1.36% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and revenue growth from $12.04B in 2025 to projected $12.5B in 2026. Analyst consensus remains positive with 57% buy ratings and a $352.88 price target, though technical indicators show selling pressure near key resistance at $321.
HLT offers growth potential from travel recovery and pipeline expansion but faces risks from premium valuation (P/E 46.64), rising debt levels (debt-to-asset ratio increased to 73.88% in 2025), and labor disputes. The stock's near-term performance depends on Q3 earnings meeting expectations of $2.38 EPS and managing global demand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
